Polycyclic pyrazines as potassium ion channel modulators

1. A compound having a structure according to Formula I:

or a pharmaceutically acceptable salt thereof,

wherein

A is substituted or unsubstituted pyridinyl, substituted or unsubstituted benzopyridinyl;

B is substituted or unsubstituted pyridinyl, substituted or unsubstituted benzopyridinyl;

W 1 is

W 2 is or —N═;

Z 1 is

Z 2 is or —N═;

Y is —NR 5 —;

s and t are independently integers from 1 to 4;

R 2A and R 2B are each independently —H, halogen or —C(O)NH 2 ;

R 1 and R 3 are independently H, —OH, —NH 2 , —NO 2 , —SO 2 NH 2 , —C(O)NH 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

wherein if s is greater than one, then each R 1 is optionally different;

wherein if t is greater than one, then each R 3 is optionally different;

wherein two R 1 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring;

wherein two R 3 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring;

wherein substituents for the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, are selected from the group consisting of —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR ″C(O) 2 R′, —NR—C (NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NRSO 2 R′, —CN and —NO 2 in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical and R′, R″, R′″and R″″are each independently hydrogen, unsubstituted heteroalkyl, unsubstituted aryl, unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups;

wherein substituents for the aryl and heteroaryl groups are selected from the group consisting of halogen, —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O) 2 R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NRSO 2 R′, —CN, —NO 2 , —R′, —N 3 , —CH(Ph) 2 , fluoro(C 1 -C 4 )alkoxy, and fluoro(C 1 -C 4 )alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system, and where R′, R″, R″and R″″are independently selected from hydrogen, alkyl, heteroalkyl, aryl and heteroaryl;

wherein the heteroaryl is selected from the group consisting of 1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3 -thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl; and

wherein the heterocycloalkyl is selected from the group consisting of 1-(1,2,5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3 -morpholinyl, tetrahvdrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, 1 -pyrrolidinyl and pyrrolidin-1-yl-2-one.

2. The compound of claim 1 , wherein

R 2A and R 2B are each independently —H, halogen or —C(O)NH 2 ; and

R 1 and R 3 are independently H, —OH, —NH 2 , —NO 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

3. The compound of claim 2 , wherein

R 1 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted 5- to 7-membered heterocycloalkyl;

R 2A and R 2B are independently H, halogen, or —C(O)NH 2 ; and

R 3 is H, —NH 2 , —NO 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

4. The compound of claim 3 , wherein

R 1 is H, —OCH 3 , methyl, unsubstituted pyrrolidine, or dimethylamino;

R 2A and R 2B are independently H, halogen, or —C(═O)—NH 2 ; and

R 3 is H, —NH 2 , —NO 2 , Cl, F, I, —OCH 3 , unsubstituted phenyl, flurophenyl, methyl, unsubstituted pyridinyl, unsubstituted thiophenyl, unsubstituted furanyl, unsubstituted pyrrolidinonyl, n—methyl piperizine, unsubstituted piperidinyl, or unsubstituted morpholinyl.

5. The compound of claim 1 , wherein

R 2A and R 2B are H;

A is

Y is —NH—;

B is

s and t are 1; and

R 1 and R 3 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

6. The compound of claim 1 , wherein

R 2A and R 2B are H;

A is substituted or unsubstituted pyridyl;

Y is —NH—;

B is

t is 1; and

R 1 and R 3 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

7. The compound of claim 6 , wherein B is

wherein

R 3 is H,

8. The compound of claim 6 , wherein B is

wherein

R 3 is methyl.

9. The compound of claim 5 , wherein A is

wherein

R 1 is methyl or

B is

wherein R 3 is H, F, or methyl.

10. The compound of claim 5 , wherein

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound claim 1 .

12. The compound of claim 1 , having the formula:

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound claim 12 .

14. A compound of claim 1 , wherein the compound is selected from the group consisting of:

(4-Methyl-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

1-[6-(6-Pyridin-2-yl-2-ylamino)-pyridin-3-yl]-pyrrolidin-2one,

(6-Pyridin-2-yl-pyrazin-2-yl)-(5-pyrrolidin-1-yl-pyridin-2yl)-amine,

Pyridin-2-yl-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5-Morpholin-4-yl-pyridin-2-yl)-(6-pyridin-2-yl- pyrazin-2-yl)-amine,

(6-Pyridin-2-yl-pyrazin-2-yl)-(3,4,5,6-tetrahydro-2H-[1,3 ′]bipyridinyl-6′-yl)-amine,

N 5 -(2-Methoxy-ethyl-N 5 -methyl-N 2 -(6-pyridin-2-pyrazin-2-yl)-pyridine-2,5-diamine,

[6-(6-Methoxy-pyridin-2-yl)-pyrazin-2-yl)]-pyridin-2-yl-amine,

Pyridin-2-yl-[6-(4-pyrrolidin-1-yl-pyridin-2-yl)-pyrazin-2-yl)]-amine,

(5-Fluoro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5-Chloro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5-Phenyl-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(4-Methyl-pyridin-2-yl)-[6-(4-pyrrolidin-1-yl-pyridin-2-yl)-pyrazin-2-yl]-amine,

[6-(4-Methyl-pyridin-2-yl)-pyrazin-2-yl]-pyridin-2-yl-amine,

(5-Fluoro-pyridin-2-yl)-[6(4-methyl-pyridin-2-yl)-pyrazin-2-yl]-amine,

[6-(5-Methyl-pyridin-2-yl)-pyrazin-2-yl]-pyridin-2-yl-amine,

N 2 -(6-Pyridin-2-yl-pyrazin-2-yl)-pyridine-2,5-diamine,

[3,3′]Bipyridinyl-6-yl-(6-pyridin-2-yl-2-yl)-amine,

[5-(3-Fluoro-phenyl)-pyridin-2-yl]-(6pyridin-2-yl-pyrazin-2-yl)-amine,

[5-(2-Methoxy-phenyl)-pyridin-2-yl]-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(4-Methyl-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-6′-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5 Bromo-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2yl)-amine, [5-(4-Dimethylamino-phenyl)-pyridin-2-yl]-(6-pyridin-2yl-pyrazin-2-yl)-amine,

(5-Chloro-pyridin-2-yl)-[6-(4pyrrolidin-1-yl-pyridin-2-yl)-pyrazin-2-yl]-amine,

(6-Fluoro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

[5-(4-Methyl-piperazin-1-yl)-pyridin-2-yl]-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5-Fluoro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(3-Bromo-6-pyridin-2-yl-pyrazin-2-yl)-pyridin-2-yl-amine,

2,6-Bis-(methoxy-pyridin-2-yl)-pyrazine,

(5-Chloro-pyridin-2-yl)-[6-(6-methoxy-pyridin-2-yl)-pyrazin-2-yl]-amine,

(5-Fluoro-pyridin-2-yl)-[6-(4-pyrrolidin-1-yl-pyridin-2-yl)-pyrazin-2-yl]-amine,

(5-Phenyl-pyridin-2-[6-(4-pyrrolidin-1-yl-pyridin-2-yl)-pyrazin-2-yl]-amine,

(5-Nitro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(5-Fluoro-pyridin-2-yl)-[6-(5-methyl-pyridin-2-yl)-pyrazin-2-yl]-amine,

N,N-Diethyl-6-(6-pyridin-2-yl-pyrazin-2-ylamino)-nicotinamide,

(6-Pyridin-2-yl-pyrazin-2-yl)-pyrimidin-2-yl-amine,

(6-Benzo[b]thiophen-2-yl-pyrazin-2-yl)-pyridin-2-yl-amine,

(3-Benzyloxy-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine

5-Pyridin-2-yl-3-(pyridin-2-ylamino)-pyrazine-2carboxylic acid amide,

(5-Bromo-pyridin-2-yl)-(5-bromo-6-pyridin-2-yl-pyrazin-2-yl)-amine,

(1-Oxy-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(3-Pentyloxy-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin2-yl)-amine,

6-(6-Pyridin-2-yl-pyrazin-2-ylamino)-nicotinamide,

4-Methyl-1-[6-(6-pyridin-2-yl-pyrazin-2-ylamino)-pyridin-3-yl]-piperazin-2-one,

2-(6-Pyridin-2-yl-pyrazin-2-ylamino)-pyridin-3-ol,

(3-Chloro-5-trifluoromethyl-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2yl)-amine,

(4-Methyl-3-nitro-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine,

(3-Benzyloxy-pyridin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine and

(4,6-Dimethoxy-pyrimidin-2-yl)-(6-pyridin-2-yl-pyrazin-2-yl)-amine.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 14 .